Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 4 3Phase 3 2Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Other hematologic neoplasm 2Head & Neck 2Gastrointestinal 2Plasma cell 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Leukemia, Myeloid, Acute 2Vomiting 1Nausea 1Myelodysplastic Syndromes 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Diseases 1

Interventions

Cyclophosphamide 414Cytarabine 336fludarabine phosphate 231Rituximab 206Methotrexate 198fludarabine 196venetoclax 174Azacitidine 174Busulfan 169Filgrastim 145Whole-Body Irradiation 143Mycophenolic Acid 143Peripheral Blood Stem Cell Transplantation 141Tacrolimus 138Etoposide 130Vincristine 112Melphalan 110Dexamethasone 109Cyclosporine 102Granulocyte Colony-Stimulating Factor 100Imatinib Mesylate 94Antilymphocyte Serum 91Daunorubicin 90Radiotherapy 84Decitabine 83Dasatinib 76Lenalidomide 75Doxorubicin 70Prednisone 68Idarubicin 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Aprepitant × Other hematologic neoplasm × Clear all
NCT01334086 2021-11-22

Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy

University Health Network, Toronto

Phase 2 Completed
41 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00954941 2015-06-25

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 7 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Myelodysplastic Syndromes, Nausea, Vomiting, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡